购物车
您的购物车当前为空
别名 Labetuzumab-SN38, IMMU-130, IMMU130, IMMU 130, hMN14-SN38
Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer.
Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 6,230 | 2-4周 | |
| 5 mg | ¥ 15,600 | 2-4周 |
| 产品描述 | Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer. |
| 别名 | Labetuzumab-SN38, IMMU-130, IMMU130, IMMU 130, hMN14-SN38 |
| 反应种属 | Human |
| 应用 | ELISA FCM Functional assay |
| 抗体种类 | Monoclonal, ADC |
| 内毒素 | <1.0 EU/mg |
| 同型 | IgG1 |
| 偶联 | SN38 |
| 基因ID | |
| Uniprot ID | |
| 靶点 | CEACAM5/CEA/CD66e |
| CAS No. | 1469876-18-3 |
| 密度 | no data available |
| 存储 | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
对于不同动物的给药剂量换算,您也可以参考 更多